Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

Cites $222bn Value Of Biologic Patent Expiries Over The Next Decade

 
• By Dave Wallace
Sandoz is continuing to invest in its operations in Slovenia (Shutterstock)

More from Manufacturing

More from Business